Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04592653 · ClinicalTrials.gov registry record · Phase 1

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

A Phase 1 study of Advanced Solid Tumor, sponsored by Mural Oncology.

Active
Registry status
Phase 1
Development phase
78
Enrollment target
6
Study locations

NCT04592653 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by Mural Oncology. The registered enrollment target is 78 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04592653, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Mural Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
6
Study locations

Study Summary

The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).

Conditions Studied

Advanced Solid Tumor

Interventions

  • BIOLOGICAL Pembrolizumab
  • BIOLOGICAL Nemvaleukin alfa

Study Locations (6)

Other

  • Hospital Clinico San Carlos - Madrid
  • CIOCC HM Sanchinarro - Madrid

Michigan

  • START Midwest - Grand Rapids

Texas

  • MD Anderson Cancer Center - Houston

Utah

  • START Mountain - West Valley City

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2020-09-30
Est. Completion 2024-12
Phase Phase 1

Sponsor

Mural Oncology

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04592653

The ClinicalTrials.gov registry entry for NCT04592653 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (60% lower). The listed sponsor is Mural Oncology, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT04592653 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Michigan, Texas.

Frequently Asked Questions

What is clinical trial NCT04592653 about?

NCT04592653 is a clinical study titled "Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)". The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).

What is the current status of trial NCT04592653?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2020-09-30. Estimated completion is 2024-12.

What conditions does trial NCT04592653 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT04592653?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nemvaleukin alfa (BIOLOGICAL).

Who is sponsoring clinical trial NCT04592653?

This trial is sponsored by Mural Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04592653 being conducted?

This trial has 6 study locations across Michigan, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.